September 13, 2023 – Page 9

Treasure & Shipwreck Recovery (OTCPK: BLIS) receives Treasure Allocation from 2021 and 2022 Seasons

Written by Customer Service on September 13, 2023. Posted in Public Companies.

Valuables include Spanish gold coins, a rare British musket, and a gemstone ring FORT PIERCE, Fla., Sept. 13, 2023 (GLOBE NEWSWIRE) — Treasure & Shipwreck Recovery, Inc. (“TSR” or “the Company”), trading as (OTCPK: BLIS), announces it has recently received its allocation of treasure it found along Florida’s Treasure Coast during the 2021 and 2022 seasons. The area worked was within the largest allowed historic shipwreck salvage operation in Florida. This zone is located within 3 nautical miles (nm) from the beach in southern Florida and, therefore, within State of Florida waters. All treasure found in these particular waters is subject to a court ordered division, including the site holder and the State of Florida, before TSR receives its portion during a selection. TSR will soon post photos of its...

Nykredit Realkredit A/S and Nykredit Bank A/S publish supplement no 2 to joint Euro Medium Term Note Programme – Nykredit Bank A/S

Written by Customer Service on September 13, 2023. Posted in Public Companies.

To Nasdaq Copenhagen Nykredit Realkredit A/S and Nykredit Bank A/S publish supplement no 2 to joint Euro Medium Term Note Programme Nykredit Realkredit A/S and Nykredit Bank A/S publish supplement no 2 dated 13 September 2023 to joint €15,000,000,000 Euro Medium Term Note Programme (“EMTN Programme”) dated 12 May 2023. Under the EMTN Programme Nykredit Realkredit may issue Subordinated Notes, Senior Non-Preferred Notes and Senior Unsecured Notes. Nykredit Bank may issue Senior Unsecured Notes. The supplement and the EMTN Programme are available for download on Nykredit’s website at nykredit.com/ir. Questions may be addressed to Morten Bækmand Nielsen, Head of ALM & Investor Relations, tel +45 44 55 15 21 or Kristian Ingemann Petersen, Attorney-at-Law, tel +45 44 55 16 78. Attachments Nykredit Realkredit...

Adaptive Announces Launch of Epic Integration for clonoSEQ®

Written by Customer Service on September 13, 2023. Posted in Public Companies.

The Adaptive-Epic integration will provide clinicians and patients with easier access to minimal residual disease (MRD) monitoring in blood cancers SEATTLE, Sept. 13, 2023 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that clonoSEQ® is now available to health care providers as a fully integrated test in Aura, Epic’s specialty diagnostics suite. This integration will allow providers to order and review clonoSEQ minimal residual disease (MRD) testing results in Epic as they would for any test performed directly at the site of care. MRD refers to the number of cancer cells that might remain in a patient’s body during and after treatment...

Nocopi Technologies Completes $5 Million Equity Offering, Further Increases Cash Position

Written by Customer Service on September 13, 2023. Posted in Public Companies.

KING OF PRUSSIA, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) — Nocopi Technologies, Inc. (OTC: NNUP), a developer of specialty reactive inks, announced that on September 11, 2023, it completed a private placement of 1.25 million shares of common stock for gross proceeds of $5 million, or a purchase price of $4.00 per share. Nocopi intends on using the net proceeds from the private placement for working capital and general corporate purposes. In connection with this transaction, Nocopi did not incur any placement fees or commissions or issue any warrants. “This capital further supports the rollout of our growth strategy into other areas and demonstrates the strong ongoing support we have received from investors,” said newly appointed Chairman and CEO Michael S. Liebowitz. A Form 8-K relating to these matters was filed with the Securities...

MariMed’s Bubby’s Baked Introduces New THC-Infused Blueberry Muffin Bites to Start the Day On a High Note

Written by Customer Service on September 13, 2023. Posted in Public Companies.

Bubby’s Baked Blueberry Muffin Bites New Bubby’s Baked, Full Spectrum, Blueberry Muffin Bites now available at select dispensaries in Massachusetts and Maryland and coming soon to Delaware. NORWOOD, Mass., Sept. 13, 2023 (GLOBE NEWSWIRE) — Leading multi-state cannabis operator MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD) headed to the blueberry bush to create the latest addition to its Bubby’s Baked™ THC-infused soft baked goods line of edibles. The Company’s new Blueberry Muffin bites are soft and baked in small batches, a made-from-scratch ode to breakfast. They join the popular Bubby’s Baked line inspired by the original pot brownie recipe and are available at select dispensaries in Massachusetts, Maryland, and Delaware. Each Bubby’s Baked Blueberry Muffin bite is an enticing...

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

Written by Customer Service on September 13, 2023. Posted in Public Companies.

BOSTON, Sept. 13, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced it will present additional preclinical data on SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Seventh Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, being held September 20 – 23, 2023 in Milan, Italy. The new data build on SNS-101’s preclinical safety and efficacy profile and provide additional insights into its conditionally active mechanism of action. SNS-101 is currently in a Phase 1/2 clinical study. Presentation Details: Title: SNS-101,...

iSpecimen Expands Provider Network to Enhance Support for Women’s Health Research

Written by Customer Service on September 13, 2023. Posted in Public Companies.

Additional Providers Increase Biospecimen Access for Researchers Focused on Cervical, Uterine and Breast Cancers, as well as Reproductive Health, Cardiovascular Disease, Autoimmune Disorders and STIs LEXINGTON, Mass., Sept. 13, 2023 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that the Company has recently expanded its global provider network to help advance women’s health research. These strategic collaborations significantly expand the availability of high-quality tissue and biofluid specimens for studies on cervical, uterine and breast cancers; reproductive health; cardiovascular disease; autoimmune disorders and STIs. Among the...

SPS Commerce Completes Acquisition of TIE Kinetix

Written by Customer Service on September 13, 2023. Posted in Mergers And Acquisitions.

TIE Kinetix strengthens company’s e-invoicing capability and expands the SPS Commerce community in Europe MINNEAPOLIS, Sept. 13, 2023 (GLOBE NEWSWIRE) — SPS Commerce, Inc. (NASDAQ: SPSC), a leader in retail cloud services, today announced it has completed the acquisition of TIE Kinetix, a leading provider of supply chain digitalization including EDI and e-invoicing in Europe. “We are pleased to officially welcome TIE Kinetix employees and customers to our growing network of trading partners around the world,” said Archie Black, CEO of SPS Commerce. “With the acquisition of TIE Kinetix, we believe SPS Commerce is well positioned to capitalize on the opportunity presented by mandatory e-invoicing regulations across Europe, while expanding our European presence to serve our growing network with access to international markets.” The...

Coop Pank AS entered into merger agreement with Coop Finants AS. Extension of the powers of the Board of Coop Finants AS

Written by Customer Service on September 13, 2023. Posted in Public Companies.

Today, Coop Pank AS entered into a notarial merger agreement with its 100% subsidiary Coop Finants AS. As a result of the merger, Coop Finants AS will dissolve, and Coop Pank AS will become its successor. The main activity of Coop Finants AS is provision of various financial services to private individuals in Estonia and mediation of card payments in the Coop Eesti stores. The aim of the merger is to simplify the structure of the Coop banking group (including making communication with the bank easier and clearer for the clients), however group’s consolidated financial position and rights and obligations will not change. The merger agreement will enter into force after receipt of an approval from the Estonian Financial Supervision and Resolution Authority and the merger is planned to be completed during the first quarter of the year 2024....

Science 37 Recognized in the Gartner® Hype Cycle™ for Life Science Clinical Development, 2023

Written by Customer Service on September 13, 2023. Posted in Public Companies.

RESEARCH TRIANGLE PARK, N.C., Sept. 13, 2023 (GLOBE NEWSWIRE) — Science 37 announced today that it has been recognized in the Gartner Hype Cycle for Life Science Clinical Development, 2023. As stated by Gartner, “This Hype Cycle explores innovative technologies that are specifically relevant to life science clinical development programs in the pharmaceutical, biotechnology, diagnostics, medical device, research institutions, and contract research sectors.” “We are honored to be recognized in the Gartner Hype Cycle for Digital Trials,” said David Coman, Chief Executive Officer at Science 37. “Innovation is core to our model, as we continue to deliver faster, more inclusive, patient-friendly clinical research.” According to the Gartner report, “Digital trials will transform the trial process, leading to improved...

Day: September 13, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice